175 related articles for article (PubMed ID: 24152053)
21. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
Bedel AN; Hemmelgarn TS; Kohli R
Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
[TBL] [Abstract][Full Text] [Related]
22. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
Yu MA; Park JM
Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
[TBL] [Abstract][Full Text] [Related]
23. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.
Pescovitz MD; Rabkin J; Merion RM; Paya CV; Pirsch J; Freeman RB; O'Grady J; Robinson C; To Z; Wren K; Banken L; Buhles W; Brown F
Antimicrob Agents Chemother; 2000 Oct; 44(10):2811-5. PubMed ID: 10991864
[TBL] [Abstract][Full Text] [Related]
24. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach.
Lalagkas PN; Iliou J; Rigo R; Miarons M; Fernández-Alarcon B; Bestard O; Cruzado JM; Melilli E; Torras J; Grinyó JM; Lloberas N; Colom H
Clin Pharmacokinet; 2023 Jun; 62(6):861-880. PubMed ID: 37140726
[TBL] [Abstract][Full Text] [Related]
26. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
[TBL] [Abstract][Full Text] [Related]
27. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
[TBL] [Abstract][Full Text] [Related]
28. Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN.
Padullés Caldés A; Colom H; Caldes A; Cerezo G; Torras J; Grinyó JM; Lloberas N
Ther Drug Monit; 2014 Jun; 36(3):371-7. PubMed ID: 24305626
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
[TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
[TBL] [Abstract][Full Text] [Related]
32. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring.
Li QY; van den Anker J; Wu YE; Hao GX; Zhao W
Expert Rev Clin Pharmacol; 2023; 16(8):727-739. PubMed ID: 36794592
[TBL] [Abstract][Full Text] [Related]
33. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
Cochrane AB
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
[TBL] [Abstract][Full Text] [Related]
34. Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients.
Franck B; Autmizguine J; Åsberg A; Théorêt Y; Marquet P; Ovetchkine P; Woillard JB
Clin Pharmacokinet; 2021 Nov; 60(11):1449-1462. PubMed ID: 34050910
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
36. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of valganciclovir's neutropenia risk in pediatric solid organ transplant recipients utilizing two dosing regimens.
Patel A; Le K; Panek N
Pediatr Transplant; 2024 Mar; 28(2):e14714. PubMed ID: 38420722
[TBL] [Abstract][Full Text] [Related]
38. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
Atay D; Erbey F; Akcay A; Dag A; Ozturk G
J Pediatr Hematol Oncol; 2015 Oct; 37(7):543-7. PubMed ID: 26207778
[TBL] [Abstract][Full Text] [Related]
39. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
40. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]